[Current patient care of giant cell arteritis in Rhineland-Palatinate].
Versorgungssituation der Riesenzellarteriitis in Rheinland‑Pfalz.
ADAPTHERA
Epidemiology
Giant cell arteritis
Out patient care
Polymyalgia rheumatica
Journal
Zeitschrift fur Rheumatologie
ISSN: 1435-1250
Titre abrégé: Z Rheumatol
Pays: Germany
ID NLM: 0414162
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
pubmed:
6
6
2018
medline:
8
10
2019
entrez:
6
6
2018
Statut:
ppublish
Résumé
Giant cell arteritis (GCA) is one of the most common forms of inflammatory vasculitis in older patients. Because of possible irreversible vision deterioration, a fastest possible diagnosis and therapy is of absolute importance. To date, there are still no reliable data to obtain an initial assessment of the outpatient health care situation of patients diagnosed with GCA in Rhineland-Palatinate. The specialists (neurologists, rheumatologists, ophthalmologists and general practitioners) participating in the statewide rheumatology network ADAPTHERA were questioned with the help of a questionnaire regarding disease frequency, activity, drug therapy and possible comorbidities. In addition, the collected data were compared and supplemented by the ambulatory coding of the Association of Statutory Health Insurance Physicians in Rhineland-Palatinate. Based on the information provided by general practitioners, 272 GCA patients were treated in Rhineland-Palatinate during the survey period. The average duration of the disease until diagnosis was 3.6 (SD ± 4.8) months. Drug therapy in the form of glucocorticoids was in first place followed by methotrexate, acetylsalicylic acid (ASA) and azathioprine. Cardiovascular diseases, chronic pain syndromes, depression, osteoporosis and diabetes mellitus were also described as comorbidities. The majority of patients with GCA are being cared for by general practitioners (GP). Long-term therapy and timely rheumatological co-treatment seem to be problematic. The primary care providers expressed their wishes for rheumatological training and further education measures. In terms of diagnosis and treatment, there is a demand to implement a "vasculitis fast-track" module.
Sections du résumé
BACKGROUND
BACKGROUND
Giant cell arteritis (GCA) is one of the most common forms of inflammatory vasculitis in older patients. Because of possible irreversible vision deterioration, a fastest possible diagnosis and therapy is of absolute importance. To date, there are still no reliable data to obtain an initial assessment of the outpatient health care situation of patients diagnosed with GCA in Rhineland-Palatinate.
METHODS
METHODS
The specialists (neurologists, rheumatologists, ophthalmologists and general practitioners) participating in the statewide rheumatology network ADAPTHERA were questioned with the help of a questionnaire regarding disease frequency, activity, drug therapy and possible comorbidities. In addition, the collected data were compared and supplemented by the ambulatory coding of the Association of Statutory Health Insurance Physicians in Rhineland-Palatinate.
RESULTS
RESULTS
Based on the information provided by general practitioners, 272 GCA patients were treated in Rhineland-Palatinate during the survey period. The average duration of the disease until diagnosis was 3.6 (SD ± 4.8) months. Drug therapy in the form of glucocorticoids was in first place followed by methotrexate, acetylsalicylic acid (ASA) and azathioprine. Cardiovascular diseases, chronic pain syndromes, depression, osteoporosis and diabetes mellitus were also described as comorbidities.
CONCLUSION
CONCLUSIONS
The majority of patients with GCA are being cared for by general practitioners (GP). Long-term therapy and timely rheumatological co-treatment seem to be problematic. The primary care providers expressed their wishes for rheumatological training and further education measures. In terms of diagnosis and treatment, there is a demand to implement a "vasculitis fast-track" module.
Identifiants
pubmed: 29869153
doi: 10.1007/s00393-018-0484-8
pii: 10.1007/s00393-018-0484-8
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
677-684Références
Medicine (Baltimore). 2005 Sep;84(5):269-76
pubmed: 16148727
Rheumatology (Oxford). 2014 May;53(5):882-9
pubmed: 24425780
Medicine (Baltimore). 2004 Mar;83(2):114-22
pubmed: 15028965
Semin Arthritis Rheum. 2013 Aug;43(1):105-12
pubmed: 23453684
J Rheumatol. 2011 Sep;38(9):2080-1
pubmed: 21885526
Arthritis Care Res (Hoboken). 2012 Nov;64(11):1720-9
pubmed: 22674883
Medicine (Baltimore). 2007 Mar;86(2):61-8
pubmed: 17435586
Arthritis Rheum. 2003 Aug 15;49(4):594-8
pubmed: 12910568
Arthritis Rheum. 2009 Oct 15;61(10):1454-61
pubmed: 19790127
Eur J Intern Med. 2009 Mar;20(2):208-12
pubmed: 19327614
Arthritis Rheum. 2006 Oct;54(10):3306-9
pubmed: 17009265
BMC Musculoskelet Disord. 2016 Jul 15;17:285
pubmed: 27421253
Ann Intern Med. 2007 May 1;146(9):621-30
pubmed: 17470830
Ann Intern Med. 1975 May;82(5):613-8
pubmed: 1137255
Arthritis Rheum. 2004 Apr;50(4):1332-7
pubmed: 15077317
Arthritis Rheum. 2002 May;46(5):1309-18
pubmed: 12115238
Arthritis Care Res (Hoboken). 2015 Mar;67(3):390-5
pubmed: 25132663
Am J Med. 2001 Aug 15;111(3):211-7
pubmed: 11530032
Curr Rheumatol Rep. 2015 Feb;17(2):6
pubmed: 25618572
Intern Med J. 2014 Jan;44(1):32-9
pubmed: 24118799
Arthritis Rheum. 1998 Nov;41(11):1960-5
pubmed: 9811050
Br J Rheumatol. 1996 Nov;35(11):1161-8
pubmed: 8948307
Br J Rheumatol. 1992 Feb;31(2):103-5
pubmed: 1737222
Semin Arthritis Rheum. 2015 Jun;44(6):717-23
pubmed: 25697557
Ann Rheum Dis. 2008 May;67(5):625-30
pubmed: 18086726
Ann Rheum Dis. 2014 Dec;73(12):2074-81
pubmed: 23897775
Ann Rheum Dis. 2018 May;77(5):636-643
pubmed: 29358285
Ann Rheum Dis. 2011 Oct;70(10):1874-5
pubmed: 21515917
Ann Rheum Dis. 2009 Mar;68(3):318-23
pubmed: 18413441
Arthritis Rheum. 2005 Apr 15;53(2):293-7
pubmed: 15818722